<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="research-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Vasc Health Risk Manag</journal-id><journal-id journal-id-type="iso-abbrev">Vasc Health Risk Manag</journal-id><journal-id journal-id-type="publisher-id">vhrm</journal-id><journal-title-group><journal-title>Vascular Health and Risk Management</journal-title></journal-title-group><issn pub-type="ppub">1176-6344</issn><issn pub-type="epub">1178-2048</issn><publisher><publisher-name>Dove</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmc">PMC9440698</article-id><article-id pub-id-type="publisher-id">382726</article-id><article-id pub-id-type="doi">10.2147/VHRM.S382726</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Research</subject></subj-group></article-categories><title-group><article-title>Risk Factors for and Treatment of Chronic Venous Disease in Thai Patients</article-title><alt-title alt-title-type="running-authors">Taengsakul</alt-title><alt-title alt-title-type="running-title">Taengsakul</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Taengsakul</surname><given-names>Nawaphan</given-names></name><xref rid="aff0001" ref-type="aff">1</xref><xref rid="an0001" ref-type="corresp"/></contrib><aff id="aff0001"><label>1</label><institution>Surgical Unit, Chulabhorn Hospital, HRH Princess Chulabhorn College of Medical Science, Chulabhorn Royal Academy</institution>, <addr-line>Bangkok</addr-line>, <country>Thailand</country></aff></contrib-group><author-notes><corresp id="an0001">Correspondence: Nawaphan Taengsakul, <institution>Surgical Unit, Chulabhorn Hospital, HRH Princess Chulabhorn College of Medical Science, Chulabhorn Royal Academy</institution>, <addr-line>906 Kamphaeng Phet 6 Road, Talat Bang Khen, Lak Si</addr-line>, <addr-line>Bangkok</addr-line>, <addr-line>10210</addr-line>, <country>Thailand</country>, <phone>Tel/Fax +66-2-576-6791</phone>, Email nawaphan.tan@cra.ac.th</corresp></author-notes><pub-date pub-type="epub"><day>30</day><month>8</month><year>2022</year></pub-date><pub-date pub-type="collection"><year>2022</year></pub-date><volume>18</volume><fpage>667</fpage><lpage>676</lpage><history><date date-type="received"><day>19</day><month>7</month><year>2022</year></date><date date-type="accepted"><day>29</day><month>8</month><year>2022</year></date></history><permissions><copyright-statement>&#x000a9; 2022 Taengsakul.</copyright-statement><copyright-year>2022</copyright-year><copyright-holder>Taengsakul.</copyright-holder><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbynclicense">https://creativecommons.org/licenses/by-nc/3.0/</ali:license_ref><license-p>This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at <ext-link ext-link-type="uri" xlink:href="https://www.dovepress.com/terms.php">https://www.dovepress.com/terms.php</ext-link> and incorporate the Creative Commons Attribution &#x02013; Non Commercial (unported, v3.0) License (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc/3.0/">http://creativecommons.org/licenses/by-nc/3.0/</ext-link>). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (<ext-link ext-link-type="uri" xlink:href="https://www.dovepress.com/terms.php">https://www.dovepress.com/terms.php</ext-link>).</license-p></license></permissions><abstract><sec sec-type="intro" id="s2001"><title>Introduction</title><p>The prevalence of chronic venous disease (CVD), a common health care problem, is still underestimated. A few previous epidemiologic studies have report Asian patients with this condition in western countries, but not in Asian countries. The aim of this study was to determine risk factors for CVD and its treatment in Thai individuals.</p></sec><sec id="s2002"><title>Methods</title><p>In this cross-sectional study, we collected data of patients with CVD visiting Chulabhorn Hospital Vascular Clinic from 1 December 2018&#x02013;1 October 2021. We reviewed medical records for patient characteristics, comorbidities, Clinical, Etiology, Anatomy, Pathophysiology (CEAP) categories, Venous Clinical Severity Score (VCSS), ultrasound findings and treatment.</p></sec><sec id="s2003"><title>Results</title><p>The study cohort comprised 260 CVD patients with CVD of mean age 61.92 &#x000b1; 12.82 years. Almost 80% of participants were female. A history of deep vein thrombosis (DVT) was the strongest risk factor for severe CVD. Other identified risk factors comprised body&#x02013;mass index (BMI) &#x0003e;30 kg/m<sup>2</sup>, and older age. The most common CEAP categories were C2 (39%) and C1 (33.8%). Superficial venous reflux was the most common location of venous reflux in this study, 67.32% of participants having great saphenous vein reflux and 16.99% small saphenous vein reflux. Only 4.76% of our cohort had both reflux and obstruction. Most of the participants had undergone compression therapy, approximately half of them complying well with wearing of stockings. Nineteen percent of our cohort had undergone sclerotherapy and 14% surgery, which comprised radiofrequency ablation in 97% of them.</p></sec><sec id="s2004"><title>Conclusion</title><p>The major risk factors for severe CVD identified in this study were deep vein thrombosis, body mass index&#x0003e;30 kg/m<sup>2</sup> and older age. The most common CEAP category was C2 (39%). GSV was the most commonly involved venous system. Involvement of numerous venous systems was a risk factor for severe CVD.</p></sec></abstract><kwd-group kwd-group-type="author"><title>Keywords</title><kwd>chronic venous disease</kwd><kwd>chronic venous insufficiency</kwd><kwd>CEAP classification</kwd><kwd>risk factor</kwd><kwd>Thailand</kwd></kwd-group><funding-group><award-group><funding-source>
<institution-wrap><institution>funding</institution></institution-wrap>
</funding-source></award-group><funding-statement>This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.</funding-statement></funding-group><counts><fig-count count="4"/><table-count count="14"/><ref-count count="22"/><page-count count="10"/></counts></article-meta></front><body><sec sec-type="intro" id="s0001"><title>Introduction</title><p>The prevalence of chronic venous disease (CVD), a common health care problem, remains underestimated because early evidence of CVD is frequently overlooked by general practitioners.<xref rid="cit0001" ref-type="bibr">1</xref> Vuylsteke et al estimated the global prevalence of CVD as relatively high, ranging from 2&#x02013;56% in men and 1&#x02013;73% in women.<xref rid="cit0001" ref-type="bibr">1</xref> Its prevalence has not been established in Asia, previous epidemiologic studies having only reported data for Asian individuals in western countries.<xref rid="cit0002" ref-type="bibr">2&#x02013;5</xref> The pathophysiology of CVD includes both morphological and functional abnormalities in the lower extremities, venous return being impaired by reflux, obstruction, or muscular pump failure.<xref rid="cit0006" ref-type="bibr">6</xref> Both superficial and deep veins are responsible for venous return in the lower limbs, these veins being connected by perforator veins. Effective venous drainage is achieved through unidirectional blood flow. Valvular dysfunction causes increasing venous hypertension, which manifests clinically as CVD.<xref rid="cit0007" ref-type="bibr">7</xref>,<xref rid="cit0008" ref-type="bibr">8</xref> Risk factors known to be associated with development and progression of CVD include obesity, smoking, prolonged orthostasis, age, and family history of CVD.<xref rid="cit0002" ref-type="bibr">2</xref> The clinical presentation of CVD is highly variable, ranging from mild telangiectasia, reticular veins, varicosity, leg edema, and hyperpigmented skin to ulceration. The severity of CVD can be categorized according to the CEAP classification. The aim of this study was to determine risk factors for advanced CVD and treatment of CVD in a Thai cohort in Thailand.</p></sec><sec id="s0002"><title>Methods</title><p>This was a cross-sectional of data of patients with CVD who had attended Chulabhorn Hospital Vascular Clinic, Bangkok, Thailand. from 1 December 2018 to 1 October 2021 being collected. The inclusion criteria were CVD diagnosed by a vascular surgeon and close follow up at Chulabhorn Hospital Vascular Clinic. The exclusion criteria included history of peripheral arterial bypass, combined arterial-venous disease, congenital venous malformations (such as Klippel-Trenaunay syndrome and Parkes-Weber syndrome) and leg edema from others causes, particularly heart disease, kidney disease and liver disease. Others exclusion criteria comprised incomplete medical records, loss to follow up and non-Thai ethnicity. We reviewed the medical records for patient characteristics, comorbidities, Clinical, Etiology, Anatomy, Pathophysiology (CEAP) categories, Venous Clinical Severity Score (VCSS), ultrasound findings and treatment. We assessed the CEAP category and VCSS in the higher scoring leg in patients with bilateral CVD. To determine the risk factors that influence advanced stage CVD, we divided the participants into two groups: mild to moderate CVD, defined as patients with clinical classification 1&#x02013;3 (C1-C3); and severe CVD, defined as patients with clinical classification 4&#x02013;6 (C4-C6) for determined the risk factors that influence advanced stage of CVD.</p><p>Ultrasound examinations were performed with the patients upright and supporting their weight on the contralateral leg. Venous reflux was elicited in two ways: using the Valsalva maneuver for the saphenofemoral junction and common femoral vein, followed by manual compression and release at distal to the point of examination for reflux from other veins. Reflux time of more than 500 milliseconds was defined as superficial venous reflux and perforator vein reflux, whereas a reflux time of more than 1000 milliseconds was defined as deep venous reflux. Iliocaval venous obstruction (ICVO) was evaluated by assessing loss of respiratory variation and reversed flow in the superior epigastric vein in all included patients. Individuals with suspected ICVO was evaluated by computed tomography venogram. This study was conducted in accordance with the Declaration of Helsinki. The Ethics Committee for Human Research of Chulabhorn Research Institution approved the study (Number 146/2564). Moreover, full written informed consent for publication of this article was obtained from the patients. Confidentiality of data was secured using codes for each record.</p><p>The statistical analysis was essentially descriptive, findings being expressed as mean &#x000b1; standard deviation for quantitative variables and counts and percentages for categorical variables All univariate analyses were performed by logistic regression. The <italic toggle="yes">&#x003c7;</italic><sup>2</sup> test was used to assess associations with outcome variables. Where data were sparse, Fisher&#x02019;s exact test was used. Exploratory bivariate analyses were also performed using the Wilcoxon signed-rank test for quantitative variables. Analysis was performed using STATA version 16.0 (Stata, College Station, TX, USA), P&#x0003c;0.050 for two-sided tests being considered to denote statistical significance.</p></sec><sec id="s0003"><title>Results</title><p>The study cohort comprised 260 CVD patients of mean age 61.92 &#x000b1; 12.82 years. Relevant patient characteristics are presented in <xref rid="t0001" ref-type="table">Table 1</xref>. Almost 80% of participants were female and most were postmenopausal. The mean BMI was 24.96 &#x000b1; 5.44; Thus, our cohort were overweight, especially those with severe CVD (C4&#x02013;C6), the mean BMI of this subgroup being 28.21 &#x000b1; 5.80. Most of our cohort were non-smokers. The rate of smoking did not differ significantly between those with mild&#x02013;moderate versus severe CVD. Two-thirds of our cohort had no relevant comorbidities. The commonest comorbidities were hypertension (HT; 21.54%), diabetes mellitus (DM; 6.9%), malignancy (3.85%) and thyroid disease (2.31%), as shown in <xref rid="t0001" ref-type="table">Table 1</xref>. Only one patient had a history of CVD treatment in another hospital. Eight percent of participants had a family history of chronic venous disease and 1.5% a personal history of deep vein thrombosis. Both legs were involved in 85% of participants, only 14% having unilateral involvement. The initial overall VCSS was 3.37 &#x000b1; 3.47, whereas it was 2.28 &#x000b1; 1.86 in patients with mild to moderate CVD and 8.30 &#x000b1; 4.66 in those with severe CVD, as shown in <xref rid="t0001" ref-type="table">Table 1</xref>. We identified older age, male sex, high BMI, DM, HT and history of DVT as risk factors for severe CVD, as shown in <xref rid="t0001" ref-type="table">Table 1</xref>. Univariate analysis (<xref rid="t0002" ref-type="table">Table 2A</xref>) showed that a history of DVT was the strongest risk factor for severe CVD (odds ratio 14.45 [1.47, 142.22] P= 0.022). Other factors significantly associated with a higher risk of severe CVD were BMI&#x0003e;30, DM, HT, male sex, and BMI 25&#x02013;29, respectively. Multivariate analysis (<xref rid="t0002" ref-type="table">Table 2B</xref>) confirmed that a history of DVT was the strongest risk factor for severe CVD. As determined by univariate analysis, multivariate analysis confirmed that BMI&#x0003e;30 and age were significantly associated with severe CVD; however, DM, male sex, HT, and BMI 25&#x02013;29 were not significantly associated with risk of severe CVD. No comorbidity was identified as protective by either univariate or multivariate analysis. However, DM, male sex, HT tended to be associated with an increased risk of severe CVD; none of these associations was statistically significant. In our cohort, 97% of patients (253 cases) had primary disease of CVD, only seven (3%) having secondary CVD. The commonest CEAP category was C2 39%, followed by C1 33.8%, C4 12%, C3 9.23%, C6 3.46% and C5 2.34% in that order. C2s was the commonest CEAP category in both sexes in our study cohort, as shown in <xref rid="t0003" ref-type="table">Table 3</xref>. Age and BMI tended to increase in parallel with CEAP category. As shown in <xref rid="t0003" ref-type="table">Table 3</xref>, the mean VCSS increased with increasing CEAP category. More than 80% of our cohort had mild to moderate CVD (C1&#x02013;C3). <xref rid="f0001" ref-type="fig">Figures 1</xref>&#x02013;<xref rid="f0002" ref-type="fig"/><xref rid="f0003" ref-type="fig"/><xref rid="f0004" ref-type="fig">4</xref> shows the correlations between risk factors and CEAP category: Patients with severe CVD were significantly older age and had higher BMIs than patients with mild to moderated CVD. Furthermore, patients with severe CVD tended to be smokers and to have a family history of CVD. Smoking and family history of CVD were more prevalent in the C6 category. The commonest site of reflux was superficial veins (71.9% of patients: greater saphenous vein [GSV] in 67.32%, small saphenous vein [SSV] in 16.99%), followed by perforator veins (45.10%), and deep veins (12.42%) (femoral vein 12.42%, popliteal vein 1.96%), as shown in <xref rid="t0004" ref-type="table">Table 4</xref>. Approximately half of our study cohort had involvement of only one venous system was involved in approximately half of our study cohort. We found a significant association between number of involved venous systems and higher CEAP categories. Only 4.76% of our participants had both reflux and obstruction. As shown in <xref rid="t0005" ref-type="table">Table 5</xref>, more than 75% of our cohort had undergone compression therapy, approximately half of them complying well with wearing of compression stockings. Sclerotherapy was performed on 19% of our participants, comprising foam sclerotherapy in 29/50 (average 1.2 sessions, range 1&#x02013;5 sessions) and liquid sclerotherapy in 23/50 (average 1.17 sessions, range 1&#x02013;2 sessions). The most commonly prescribed medication was micronized purified flavonoid fraction (17.76%), followed by Aescin (12.02%). Surgery was performed on 14% of our cohort, this mostly comprising venous radiofrequency ablation (97%). Overall, VCSS scores improved by 3.62 &#x000b1; 2.25, decreasing by 2.96 &#x000b1; 1.60 in those with mild to moderate CVD group and by 5.57 &#x000b1; 2.74 in those with severe CVD.<table-wrap position="float" id="t0001"><label>Table 1</label><caption><p>Patient Characteristics According to Severity of Chronic Venous Disease</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="1" colspan="1">Risk Factor</th><th rowspan="1" colspan="1">Total Cases (N=260)</th><th rowspan="1" colspan="1">Mild to Moderate CVD (C0-C3) (N=213)</th><th rowspan="1" colspan="1">Severe CVD (C4-C6) (N=47)</th><th rowspan="1" colspan="1">P-value</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">Age (years) (mean &#x000b1; SD)</td><td rowspan="1" colspan="1">61.92 &#x000b1; 12.82</td><td rowspan="1" colspan="1">59.57 &#x000b1; 11.83</td><td rowspan="1" colspan="1">72.57 &#x000b1; 11.79</td><td rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td rowspan="1" colspan="1">&#x02003;- 18&#x02013;40</td><td rowspan="1" colspan="1">20 (7.69)</td><td rowspan="1" colspan="1">19 (8.92)</td><td rowspan="1" colspan="1">1 (2.13)</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#x02003;- 41&#x02013;60</td><td rowspan="1" colspan="1">90 (34.62)</td><td rowspan="1" colspan="1">84 (39.44)</td><td rowspan="1" colspan="1">6 (12.77)</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#x02003;- &#x0003e;60</td><td rowspan="1" colspan="1">150 (57.69)</td><td rowspan="1" colspan="1">110 (51.64)</td><td rowspan="1" colspan="1">40 (85.11)</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Sex</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">0.007</td></tr><tr><td rowspan="1" colspan="1">&#x02003;- Male</td><td rowspan="1" colspan="1">60 (23.08)</td><td rowspan="1" colspan="1">42 (19.72)</td><td rowspan="1" colspan="1">18 (38.30)</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#x02003;- Female</td><td rowspan="1" colspan="1">200 (76.92)</td><td rowspan="1" colspan="1">171 (80.28)</td><td rowspan="1" colspan="1">29 (61.70)</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">BMI (mean &#x000b1; SD)</td><td rowspan="1" colspan="1">24.96 &#x000b1; 5.44</td><td rowspan="1" colspan="1">24.25 &#x000b1; 5.11</td><td rowspan="1" colspan="1">28.21 &#x000b1; 5.80</td><td rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td rowspan="1" colspan="1">BMI group</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td rowspan="1" colspan="1">&#x02003;- &#x0003c;25</td><td rowspan="1" colspan="1">144 (55.38)</td><td rowspan="1" colspan="1">129 (60.56)</td><td rowspan="1" colspan="1">15 (31.91)</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#x02003;- 25&#x02013;29</td><td rowspan="1" colspan="1">71 (27.31)</td><td rowspan="1" colspan="1">56 (26.29)</td><td rowspan="1" colspan="1">15 (31.91)</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#x02003;- &#x0003e;30</td><td rowspan="1" colspan="1">45 (17.31)</td><td rowspan="1" colspan="1">28 (13.15)</td><td rowspan="1" colspan="1">17 (36.17)</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Smoking</td><td rowspan="1" colspan="1">11 (4.23)</td><td rowspan="1" colspan="1">8 (3.76)</td><td rowspan="1" colspan="1">3 (6.38)</td><td rowspan="1" colspan="1">0.428</td></tr><tr><td rowspan="1" colspan="1">Oral contraceptive pill</td><td rowspan="1" colspan="1">1 (0.39)</td><td rowspan="1" colspan="1">1 (0.47)</td><td rowspan="1" colspan="1">0 (0.00)</td><td rowspan="1" colspan="1">1.000</td></tr><tr><td rowspan="1" colspan="1">Menopause</td><td rowspan="1" colspan="1">185 (71.71)</td><td rowspan="1" colspan="1">153 (72.17)</td><td rowspan="1" colspan="1">32 (69.57)</td><td rowspan="1" colspan="1">0.722</td></tr><tr><td rowspan="1" colspan="1">Comorbidity</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#x02003;Diabetes mellitus</td><td rowspan="1" colspan="1">18 (6.92)</td><td rowspan="1" colspan="1">10 (4.69)</td><td rowspan="1" colspan="1">8 (17.02)</td><td rowspan="1" colspan="1">0.007</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Hypertension</td><td rowspan="1" colspan="1">56 (21.54)</td><td rowspan="1" colspan="1">36 (16.90)</td><td rowspan="1" colspan="1">20 (42.55)</td><td rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Malignant disease</td><td rowspan="1" colspan="1">10 (3.85)</td><td rowspan="1" colspan="1">7 (3.29)</td><td rowspan="1" colspan="1">3 (6.38)</td><td rowspan="1" colspan="1">0.394</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Thyroid disease</td><td rowspan="1" colspan="1">6 (2.31)</td><td rowspan="1" colspan="1">4 (1.88)</td><td rowspan="1" colspan="1">2 (4.26)</td><td rowspan="1" colspan="1">0.297</td></tr><tr><td rowspan="1" colspan="1">&#x02003;No relevant comorbidity</td><td rowspan="1" colspan="1">171 (65.77)</td><td rowspan="1" colspan="1">150 (70.42)</td><td rowspan="1" colspan="1">21 (44.68)</td><td rowspan="1" colspan="1">0.001</td></tr><tr><td rowspan="1" colspan="1">Family history of chronic venous disease</td><td rowspan="1" colspan="1">23 (8.85)</td><td rowspan="1" colspan="1">18 (8.45)</td><td rowspan="1" colspan="1">5 (10.64)</td><td rowspan="1" colspan="1">0.579</td></tr><tr><td rowspan="1" colspan="1">History of DVT</td><td rowspan="1" colspan="1">4 (1.54)</td><td rowspan="1" colspan="1">1 (0.47)</td><td rowspan="1" colspan="1">3 (6.38)</td><td rowspan="1" colspan="1">0.020</td></tr><tr><td rowspan="1" colspan="1">Location of chronic venous disease</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#x02003;- Right leg</td><td rowspan="1" colspan="1">17 (6.67)</td><td rowspan="1" colspan="1">17 (8.17)</td><td rowspan="1" colspan="1">0 (0.00)</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#x02003;- Left leg</td><td rowspan="1" colspan="1">20 (7.84)</td><td rowspan="1" colspan="1">17 (8.17)</td><td rowspan="1" colspan="1">3 (6.38)</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#x02003;- Both legs</td><td rowspan="1" colspan="1">218 (85.49)</td><td rowspan="1" colspan="1">174 (83.65)</td><td rowspan="1" colspan="1">44 (93.62)</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Initial VCSS score (mean &#x000b1; SD)</td><td rowspan="1" colspan="1">3.37 &#x000b1; 3.47</td><td rowspan="1" colspan="1">2.28 &#x000b1; 1.86</td><td rowspan="1" colspan="1">8.30 &#x000b1; 4.66</td><td rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td rowspan="1" colspan="1">Post intervention VCSS score (mean &#x000b1; SD)</td><td rowspan="1" colspan="1">1.61 &#x000b1; 2.73</td><td rowspan="1" colspan="1">0.48 &#x000b1; 0.79</td><td rowspan="1" colspan="1">4.91 &#x000b1; 3.62</td><td rowspan="1" colspan="1">&#x0003c;0.001</td></tr></tbody></table><table-wrap-foot><fn id="tfn0001"><p><bold>Note</bold>: According to univariate logistic regression.</p></fn><fn id="tfn0002"><p><bold>Abbreviations</bold>: BMI, body mass index; CVD, chronic venous disease; DVT, deep vein thrombosis; VCSS, venous clinical severity classification.</p></fn></table-wrap-foot></table-wrap>
<table-wrap position="float" id="t0002"><label>Table 2</label><caption><p>Risk Factors for Severe CVD in Our Study Cohort</p></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="3" rowspan="1">(A) Result of univariate analysis of risk factors for severe CVD</th></tr><tr><th rowspan="1" colspan="1">Risk factor</th><th rowspan="1" colspan="1">Odd ratio (95% CI)</th><th rowspan="1" colspan="1">P-value</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">History of DVT</td><td rowspan="1" colspan="1">14.45 (1.47, 142.22)</td><td rowspan="1" colspan="1">0.022</td></tr><tr><td rowspan="1" colspan="1">BMI&#x0003e;30</td><td rowspan="1" colspan="1">5.22 (2.33, 11.69)</td><td rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td rowspan="1" colspan="1">Diabetes mellitus</td><td rowspan="1" colspan="1">4.16 (1.55, 11.22)</td><td rowspan="1" colspan="1">0.005</td></tr><tr><td rowspan="1" colspan="1">Hypertension</td><td rowspan="1" colspan="1">3.64 (1.84, 7.19)</td><td rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td rowspan="1" colspan="1">Male sex</td><td rowspan="1" colspan="1">2.53 (1.28, 4.98)</td><td rowspan="1" colspan="1">0.007</td></tr><tr><td rowspan="1" colspan="1">BMI 25&#x02013;29</td><td rowspan="1" colspan="1">2.30 (1.05, 5.03)</td><td rowspan="1" colspan="1">0.036</td></tr><tr><td rowspan="1" colspan="1">Age</td><td rowspan="1" colspan="1">1.12 (1.08, 1.17)</td><td rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td rowspan="1" colspan="1">No underlying disease</td><td rowspan="1" colspan="1">0.34 (0.18, 0.65)</td><td rowspan="1" colspan="1">0.001</td></tr><tr><td colspan="3" rowspan="1"><bold>(B) Result of multivariate analysis of risk factors for severe CVD</bold></td></tr><tr><td rowspan="1" colspan="1"><bold>Risk factor</bold></td><td rowspan="1" colspan="1"><bold>Odd ratio (95% CI)</bold></td><td rowspan="1" colspan="1"><bold>P-value</bold></td></tr><tr><td rowspan="1" colspan="1">History of DVT</td><td rowspan="1" colspan="1">16.77 (0.83, 337.35)</td><td rowspan="1" colspan="1">0.046</td></tr><tr><td rowspan="1" colspan="1">BMI&#x0003e;30</td><td rowspan="1" colspan="1">6.26 (1.44, 27.14)</td><td rowspan="1" colspan="1">0.014</td></tr><tr><td rowspan="1" colspan="1">Diabetes mellitus</td><td rowspan="1" colspan="1">3.59 (0.56, 22.84)</td><td rowspan="1" colspan="1">0.176</td></tr><tr><td rowspan="1" colspan="1">Male sex</td><td rowspan="1" colspan="1">2.52 (0.75, 8.51)</td><td rowspan="1" colspan="1">0.136</td></tr><tr><td rowspan="1" colspan="1">Hypertension</td><td rowspan="1" colspan="1">1.28 (0.37, 4.41)</td><td rowspan="1" colspan="1">0.696</td></tr><tr><td rowspan="1" colspan="1">Age</td><td rowspan="1" colspan="1">1.17 (1.09, 1.25)</td><td rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td rowspan="1" colspan="1">BMI 25&#x02013;29</td><td rowspan="1" colspan="1">0.75 (0.20, 2.85)</td><td rowspan="1" colspan="1">0.669</td></tr><tr><td rowspan="1" colspan="1">No underlying disease</td><td rowspan="1" colspan="1">0.22 (0.18, 0.65)</td><td rowspan="1" colspan="1">0.026</td></tr></tbody></table><table-wrap-foot><fn id="tfn0003"><p><bold>Abbreviations</bold>: BMI, body mass index; CI, confidence interval; OR, odds ratio.</p></fn></table-wrap-foot></table-wrap>
<table-wrap position="float" id="t0003"><label>Table 3</label><caption><p>Risk Factors for CVD and VCSS According to CEAP Category</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="1" colspan="1">CEAP Classification</th><th rowspan="1" colspan="1">Number of Patients and Limb (%)</th><th rowspan="1" colspan="1">Men</th><th rowspan="1" colspan="1">Women</th><th rowspan="1" colspan="1">Mean Age (Years) (Mean &#x000b1; SD)</th><th rowspan="1" colspan="1">BMI (Mean &#x000b1; SD)</th><th rowspan="1" colspan="1">VCSS Score (Mean &#x000b1; SD)</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">C1</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1"><list list-type="bullet"><list-item><p>C1a</p></list-item></list></td><td rowspan="1" colspan="1">51 (19.62)</td><td rowspan="1" colspan="1">3 (5.00)</td><td rowspan="1" colspan="1">48 (24.00)</td><td rowspan="1" colspan="1">57.20 &#x000b1; 12.54</td><td rowspan="1" colspan="1">22.17 &#x000b1; 3.81</td><td rowspan="1" colspan="1">0.33 &#x000b1; 0.53</td></tr><tr><td rowspan="1" colspan="1"><list list-type="bullet"><list-item><p>C1s</p></list-item></list></td><td rowspan="1" colspan="1">37 (14.23)</td><td rowspan="1" colspan="1">1 (1.67)</td><td rowspan="1" colspan="1">36 (18.00)</td><td rowspan="1" colspan="1">56.19 &#x000b1; 11.45</td><td rowspan="1" colspan="1">22.89 &#x000b1; 3.69</td><td rowspan="1" colspan="1">1.57 &#x000b1; 0.73</td></tr><tr><td rowspan="1" colspan="1">C2</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1"><list list-type="bullet"><list-item><p>C2a</p></list-item></list></td><td rowspan="1" colspan="1">31 (11.92)</td><td rowspan="1" colspan="1">13 (21.67)</td><td rowspan="1" colspan="1">18 (9.00)</td><td rowspan="1" colspan="1">59.32 &#x000b1; 13.00</td><td rowspan="1" colspan="1">24.10 &#x000b1; 4.81</td><td rowspan="1" colspan="1">1.45 &#x000b1; 0.99</td></tr><tr><td rowspan="1" colspan="1"><list list-type="bullet"><list-item><p>C2s</p></list-item></list></td><td rowspan="1" colspan="1">70 (26.92)</td><td rowspan="1" colspan="1">21 (35.00)</td><td rowspan="1" colspan="1">49 (24.50)</td><td rowspan="1" colspan="1">61.41 &#x000b1; 10.78</td><td rowspan="1" colspan="1">25.97 &#x000b1; 6.00</td><td rowspan="1" colspan="1">3.76 &#x000b1; 1.37</td></tr><tr><td rowspan="1" colspan="1">C3</td><td rowspan="1" colspan="1">24 (9.23)</td><td rowspan="1" colspan="1">4 (6.67)</td><td rowspan="1" colspan="1">20 (10.00)</td><td rowspan="1" colspan="1">64.79 &#x000b1; 10.21</td><td rowspan="1" colspan="1">25.92 &#x000b1; 4.98</td><td rowspan="1" colspan="1">4.29 &#x000b1; 1.57</td></tr><tr><td rowspan="1" colspan="1">C4</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1"><list list-type="bullet"><list-item><p>C4a</p></list-item></list></td><td rowspan="1" colspan="1">17 (6.54)</td><td rowspan="1" colspan="1">6 (10.00)</td><td rowspan="1" colspan="1">11 (5.50)</td><td rowspan="1" colspan="1">75.94 &#x000b1; 8.76</td><td rowspan="1" colspan="1">25.65 &#x000b1; 4.58</td><td rowspan="1" colspan="1">5.35 &#x000b1; 3.30</td></tr><tr><td rowspan="1" colspan="1"><list list-type="bullet"><list-item><p>C4b</p></list-item></list></td><td rowspan="1" colspan="1">15 (5.77)</td><td rowspan="1" colspan="1">6 (10.00)</td><td rowspan="1" colspan="1">9 (4.50)</td><td rowspan="1" colspan="1">72.87 &#x000b1; 13.18</td><td rowspan="1" colspan="1">28.27 &#x000b1; 5.99</td><td rowspan="1" colspan="1">8.53 &#x000b1; 2.50</td></tr><tr><td rowspan="1" colspan="1">C5</td><td rowspan="1" colspan="1">6 (2.31)</td><td rowspan="1" colspan="1">3 (5.00)</td><td rowspan="1" colspan="1">3 (1.50)</td><td rowspan="1" colspan="1">71.17 &#x000b1; 11.50</td><td rowspan="1" colspan="1">31.33 &#x000b1; 4.76</td><td rowspan="1" colspan="1">9.33 &#x000b1; 3.83</td></tr><tr><td rowspan="1" colspan="1">C6</td><td rowspan="1" colspan="1">9 (3.46)</td><td rowspan="1" colspan="1">3 (5.00)</td><td rowspan="1" colspan="1">6 (3.00)</td><td rowspan="1" colspan="1">66.67 &#x000b1; 13.92</td><td rowspan="1" colspan="1">30.89 &#x000b1; 6.70</td><td rowspan="1" colspan="1">12.78 &#x000b1; 6.40</td></tr><tr><td rowspan="1" colspan="1">Total</td><td rowspan="1" colspan="1">260 (100.00)</td><td rowspan="1" colspan="1">60 (100.00)</td><td rowspan="1" colspan="1">200 (100.00)</td><td rowspan="1" colspan="1">61.92 &#x000b1; 12.82</td><td rowspan="1" colspan="1">24.96 &#x000b1; 5.44</td><td rowspan="1" colspan="1">3.37 &#x000b1; 3.47</td></tr></tbody></table><table-wrap-foot><fn id="tfn0004"><p><bold>Note</bold>: Based on the CEAP, clinical classification of chronic venous disorders (CEAP).</p></fn><fn id="tfn0005"><p><bold>Abbreviations</bold>: BMI, Body Mass Index; CEAP, clinical classification of chronic venous disorders; VCSS, venous clinical severity score.</p></fn></table-wrap-foot></table-wrap>
<table-wrap position="float" id="t0004"><label>Table 4</label><caption><p>Ultrasound Findings According to Severity of CVD</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="1" colspan="1">Ultrasound Finding</th><th rowspan="1" colspan="1">Total Case n=153 (%)</th><th rowspan="1" colspan="1">Mild to Moderate CVD (C0-C3) n=110 (%)</th><th rowspan="1" colspan="1">Severe CVD (C4-C6) n=43 (%)</th><th rowspan="1" colspan="1">P-value</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">Superficial vein reflux</td><td rowspan="1" colspan="1">110 (71.90)</td><td rowspan="1" colspan="1">77 (70.00)</td><td rowspan="1" colspan="1">33 (76.74)</td><td rowspan="1" colspan="1">0.405</td></tr><tr><td rowspan="1" colspan="1"><list list-type="bullet"><list-item><p>GSV reflux</p></list-item></list></td><td rowspan="1" colspan="1">103 (67.32)</td><td rowspan="1" colspan="1">72 (65.45)</td><td rowspan="1" colspan="1">31 (72.09)</td><td rowspan="1" colspan="1">0.432</td></tr><tr><td rowspan="1" colspan="1"><list list-type="bullet"><list-item><p>SSV reflux</p></list-item></list></td><td rowspan="1" colspan="1">26 (16.99)</td><td rowspan="1" colspan="1">14 (12.73)</td><td rowspan="1" colspan="1">12 (27.91)</td><td rowspan="1" colspan="1">0.028</td></tr><tr><td rowspan="1" colspan="1">Perforator reflux</td><td rowspan="1" colspan="1">69 (45.10)</td><td rowspan="1" colspan="1">37 (33.64)</td><td rowspan="1" colspan="1">32 (74.42)</td><td rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td rowspan="1" colspan="1">Deep vein reflux</td><td rowspan="1" colspan="1">19 (12.42)</td><td rowspan="1" colspan="1">11 (10.00)</td><td rowspan="1" colspan="1">8 (18.60)</td><td rowspan="1" colspan="1">0.153</td></tr><tr><td rowspan="1" colspan="1"><list list-type="bullet"><list-item><p>Femoral vein reflux</p></list-item></list></td><td rowspan="1" colspan="1">19 (12.42)</td><td rowspan="1" colspan="1">11 (10.00)</td><td rowspan="1" colspan="1">8 (18.60)</td><td rowspan="1" colspan="1">0.147</td></tr><tr><td rowspan="1" colspan="1"><list list-type="bullet"><list-item><p>Popliteal vein reflux</p></list-item></list></td><td rowspan="1" colspan="1">3 (1.96)</td><td rowspan="1" colspan="1">1 (0.91)</td><td rowspan="1" colspan="1">2 (4.65)</td><td rowspan="1" colspan="1">0.191</td></tr><tr><td rowspan="1" colspan="1">Number of involved venous systems</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">0.005</td></tr><tr><td rowspan="1" colspan="1"><list list-type="bullet"><list-item><p>None</p></list-item></list></td><td rowspan="1" colspan="1">21 (13.64)</td><td rowspan="1" colspan="1">20 (18.02)</td><td rowspan="1" colspan="1">1 (2.33)</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1"><list list-type="bullet"><list-item><p>One</p></list-item></list></td><td rowspan="1" colspan="1">74 (48.05)</td><td rowspan="1" colspan="1">57 (51.35)</td><td rowspan="1" colspan="1">17 (39.53)</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1"><list list-type="bullet"><list-item><p>Two</p></list-item></list></td><td rowspan="1" colspan="1">49 (31.82)</td><td rowspan="1" colspan="1">29 (26.13)</td><td rowspan="1" colspan="1">20 (46.51)</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1"><list list-type="bullet"><list-item><p>Three</p></list-item></list></td><td rowspan="1" colspan="1">10 (6.49)</td><td rowspan="1" colspan="1">5 (4.50)</td><td rowspan="1" colspan="1">5 (11.63)</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Reflux +obstruction</td><td rowspan="1" colspan="1">7 (4.76)</td><td rowspan="1" colspan="1">6 (5.71)</td><td rowspan="1" colspan="1">1 (2.38)</td><td rowspan="1" colspan="1">0.673</td></tr></tbody></table><table-wrap-foot><fn id="tfn0006"><p><bold>Note</bold>: According to univariate logistic regression.</p></fn><fn id="tfn0007"><p><bold>Abbreviations</bold>: CVD, Chronic venous disease; GSV, great saphenous vein; SSV, small saphenous vein.</p></fn></table-wrap-foot></table-wrap>
<table-wrap position="float" id="t0005"><label>Table 5</label><caption><p>Treatment According to Severity of CVD</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="1" colspan="1">Treatment</th><th rowspan="1" colspan="1">Total Case N=260 (%)</th><th rowspan="1" colspan="1">Mild to Moderate CVD (C0-C3) N=213 (%)</th><th rowspan="1" colspan="1">Severe CVD (C4-C6) N=47 (%)</th><th rowspan="1" colspan="1">P-value</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">Compression therapy</td><td rowspan="1" colspan="1">194 (74.62)</td><td rowspan="1" colspan="1">159 (73.71)</td><td rowspan="1" colspan="1">37 (78.72)</td><td rowspan="1" colspan="1">0.475<sup>a</sup></td></tr><tr><td rowspan="1" colspan="1">Good compliance</td><td rowspan="1" colspan="1">112 (43.08)</td><td rowspan="1" colspan="1">92 (43.19)</td><td rowspan="1" colspan="1">20 (42.55)</td><td rowspan="1" colspan="1">0.936<sup>a</sup></td></tr><tr><td rowspan="1" colspan="1">Sclerotherapy</td><td rowspan="1" colspan="1">50 (19.38)</td><td rowspan="1" colspan="1">37 (17.45)</td><td rowspan="1" colspan="1">13 (28.26)</td><td rowspan="1" colspan="1">0.093<sup>a</sup></td></tr><tr><td rowspan="1" colspan="1">Foam sclerotherapy</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">0.364<sup>b</sup></td></tr><tr><td rowspan="1" colspan="1"><list list-type="bullet"><list-item><p>One session</p></list-item></list></td><td rowspan="1" colspan="1">25 (86.21)</td><td rowspan="1" colspan="1">16 (94.12)</td><td rowspan="1" colspan="1">9 (75.00)</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1"><list list-type="bullet"><list-item><p>Two sessions</p></list-item></list></td><td rowspan="1" colspan="1">3 (10.34)</td><td rowspan="1" colspan="1">1 (5.88)</td><td rowspan="1" colspan="1">2 (16.67)</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1"><list list-type="bullet"><list-item><p>Five sessions</p></list-item></list></td><td rowspan="1" colspan="1">1 (3.45)</td><td rowspan="1" colspan="1">0 (0.00)</td><td rowspan="1" colspan="1">1 (8.33)</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Liquid sclerotherapy</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1"><list list-type="bullet"><list-item><p>One session</p></list-item></list></td><td rowspan="1" colspan="1">19 (82.61)</td><td rowspan="1" colspan="1">19 (82.61)</td><td rowspan="1" colspan="1">-</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1"><list list-type="bullet"><list-item><p>Two sessions</p></list-item></list></td><td rowspan="1" colspan="1">4 (17.39)</td><td rowspan="1" colspan="1">4 (17.39)</td><td rowspan="1" colspan="1">-</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Medication</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1"><list list-type="bullet"><list-item><p>Micronized purified flavonoid fraction</p></list-item></list></td><td rowspan="1" colspan="1">46 (17.76)</td><td rowspan="1" colspan="1">18 (9.49)</td><td rowspan="1" colspan="1">28 (59.57)</td><td rowspan="1" colspan="1">&#x0003c;0.001<sup>a</sup></td></tr><tr><td rowspan="1" colspan="1"><list list-type="bullet"><list-item><p>Pentoxifylline</p></list-item></list></td><td rowspan="1" colspan="1">1 (0.39)</td><td rowspan="1" colspan="1">0 (0.00)</td><td rowspan="1" colspan="1">1 (2.13)</td><td rowspan="1" colspan="1">0.183<sup>b</sup></td></tr><tr><td rowspan="1" colspan="1"><list list-type="bullet"><list-item><p>Sulodexide</p></list-item></list></td><td rowspan="1" colspan="1">3 (1.16)</td><td rowspan="1" colspan="1">0 (0.00)</td><td rowspan="1" colspan="1">3 (3.38)</td><td rowspan="1" colspan="1">0.006<sup>b</sup></td></tr><tr><td rowspan="1" colspan="1"><list list-type="bullet"><list-item><p>Aescin</p></list-item></list></td><td rowspan="1" colspan="1">31 (12.02)</td><td rowspan="1" colspan="1">14 (6.64)</td><td rowspan="1" colspan="1">17 (36.17)</td><td rowspan="1" colspan="1">&#x0003c;0.001<sup>a</sup></td></tr><tr><td rowspan="1" colspan="1">Surgery</td><td rowspan="1" colspan="1">36 (14.06)</td><td rowspan="1" colspan="1">19 (9.09)</td><td rowspan="1" colspan="1">17 (36.17)</td><td rowspan="1" colspan="1">&#x0003c;0.001<sup>a</sup></td></tr><tr><td rowspan="1" colspan="1">Option of Surgery</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">0.429<sup>b</sup></td></tr><tr><td rowspan="1" colspan="1"><list list-type="bullet"><list-item><p>Endovenous radiofrequency ablation</p></list-item></list></td><td rowspan="1" colspan="1">34 (97.14)</td><td rowspan="1" colspan="1">20 (100.00)</td><td rowspan="1" colspan="1">14 (93.33)</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1"><list list-type="bullet"><list-item><p>Glue injection</p></list-item></list></td><td rowspan="1" colspan="1">1 (2.86)</td><td rowspan="1" colspan="1">0 (0.00)</td><td rowspan="1" colspan="1">1 (6.67)</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Improvement in VCSS after intervention</td><td rowspan="1" colspan="1">3.62 &#x000b1; 2.25</td><td rowspan="1" colspan="1">2.96 &#x000b1; 1.60</td><td rowspan="1" colspan="1">5.57 &#x000b1; 2.74</td><td rowspan="1" colspan="1">&#x0003c;0.001<sup>c</sup></td></tr></tbody></table><table-wrap-foot><fn id="tfn0008"><p><bold>Notes</bold>: <sup>a</sup>Pearson chi-square. <sup>b</sup>Fisher&#x02019;s exact. <sup>c</sup>Wilcoxon signed-rank test.</p></fn><fn id="tfn0009"><p><bold>Abbreviations</bold>: CVD, chronic venous disease; VCSS, Venous Clinical Severity Score.</p></fn></table-wrap-foot></table-wrap>
<fig position="float" id="f0001" fig-type="figure"><label>Figure 1</label><caption><p>Correlations between age (years) and CEAP category. (<bold>A</bold>) Age ranges for each CEAP category. (<bold>B</bold>) Age ranges according to severity of CVD, showing that patients with severe CVD (C4-6) are significantly older than those with mild to moderate CVD (C1-C3).</p></caption><graphic xlink:href="VHRM-18-667-g0001" content-type="print-only" position="float"/></fig><fig position="float" id="f0002" fig-type="figure"><label>Figure 2</label><caption><p>Correlations between BMI and CEAP category. (<bold>A</bold>) BMI ranges of each CEAP category. (<bold>B</bold>) BMI ranges according to severity of CVD, showing that patients with severe CVD (C4-6) have significantly higher BMIs than patients with mild to moderate CVD (C1-C3).</p></caption><graphic xlink:href="VHRM-18-667-g0002" content-type="print-only" position="float"/><attrib><bold>Abbreviations</bold>: BMI, body mass index; CEAP, clinical classification of chronic venous disorders; CVD, chronic venous disease.</attrib></fig><fig position="float" id="f0003" fig-type="figure"><label>Figure 3</label><caption><p>Correlations between smoking and CEAP category. (<bold>A</bold>) Proportion of smokers in each CEAP category, showing the highest prevalence of smoking is in the C6 category. (<bold>B</bold>) Proportion of smokers according to severity of CVD, showing smoking tends to be more prevalent in patients with severe CVD (C4-6) than in those with mild to moderate CVD (C1-C3).</p></caption><graphic xlink:href="VHRM-18-667-g0003" content-type="print-only" position="float"/><attrib><bold>Abbreviation</bold>: CEAP, clinical classification of chronic venous disorders.</attrib></fig><fig position="float" id="f0004" fig-type="figure"><label>Figure 4</label><caption><p>Correlations between family history of CVD and CEAP category. (<bold>A</bold>) Prevalence of family history of CVD in each CEAP category. The prevalence is highest in the C6 category. (<bold>B</bold>) Patients with severe CVD (C4-6) tend to be more likely to have a positive family history of CVD than patients with mild to moderate CVD (C1-C3).</p></caption><graphic xlink:href="VHRM-18-667-g0004" content-type="print-only" position="float"/><attrib><bold>Abbreviations</bold>: CEAP, clinical classification of chronic venous disorders; CVD, chronic venous disease.</attrib></fig></p></sec><sec id="s0004"><title>Discussion</title><p>The study cohort comprised 260 patients with diagnoses of CVD. The commonest age group of participants was &#x0003e;60 years and the participants were predominantly female. Older age was significantly associated with severe CVD (P&#x0003c;0.001). The San Diego study reported an odds ratio of up to 4.85 for older age; this association was statistically significant.<xref rid="cit0002" ref-type="bibr">2</xref> In the Bonn Vein Study, the most important risk factor for CVD was older age, especially ages 70&#x02013;79 in whom the risk was 15.9-fold that of younger patients.<xref rid="cit0009" ref-type="bibr">9</xref> Over 75% of our cohort were female but that male sex tended to be associated with severe CVD. Most previous researchers have reported that CVD is more prevalent in female than in male patients, as was the case in our study. One previous study reported that female patients had significantly more severe CVD (higher CEAP category) than did male patients.<xref rid="cit0001" ref-type="bibr">1</xref> The Edinburgh Vein Study reported the greater prevalence of severe CVD in male than in female patients.<xref rid="cit0010" ref-type="bibr">10</xref> This is in agreement with the present findings. Although more than 30% of our study patients were of normal weight (BMI &#x0003c;25 kg/m<sup>2</sup>), the mean BMI met the criteria for overweight. Additionally, high BMI (BMI&#x0003e;30 kg/m<sup>2</sup>) was significantly associated with severe CVD (CEAP category C4&#x02013;C6) (P =0.014). A previous study found an association between BMI &#x0003e;30 kg/m<sup>2</sup> and increased risk of CVD, the odds ratios for men and women being 6.5 and 3.1, respectively.<xref rid="cit0011" ref-type="bibr">11</xref> Furthermore, DM and HT tended to be associated with a higher risk of severe CVD. Patients with no comorbidities were at lower risk of severe CVD than were those with relevant comorbidities (P=0.026). A previous study found that patients with CVD had more comorbidities than the general population.<xref rid="cit0012" ref-type="bibr">12</xref> Oral contraception was not a risk factor for CVD in the present study, contrary to the finding of a previous study.<xref rid="cit0009" ref-type="bibr">9</xref> A history of DVT was a risk factor for severe CVD. Although we identified neither smoking nor a family history of CVD as risk factors for severe CVD in the present study, patients in the C6 category were more likely to be smokers and to have a family history of CVD, as shown in <xref rid="f0001" ref-type="fig">Figure 1</xref>. A previous study showed a positive correlation between smoking and severity of CVD only in men aged 35&#x02013;65 years; however, these researchers did not provide data concerning the relationship between smoking and the severity of CVD in women.<xref rid="cit0001" ref-type="bibr">1</xref> Although, we did not identify a significant relationship between family history of CVD and severe CVD in our study, several studies have found a correlation between these variables.<xref rid="cit0001" ref-type="bibr">1</xref>,<xref rid="cit0009" ref-type="bibr">9</xref> A review of published reports revealed considerable evidence for a strong association between family history of CVD and the presence of varicose veins. According one study, more than 70% of patients with varicose veins have a family history of CVD.<xref rid="cit0013" ref-type="bibr">13</xref> In a study of 4033 nuclear families, heritability of CVD was identified in 17.3%, suggesting a genetic component.<xref rid="cit0014" ref-type="bibr">14</xref> A twins&#x02019; study found a higher degree of concordance between monozygotic twins (75%) than between dizygotic twins (52%).<xref rid="cit0015" ref-type="bibr">15</xref> A case-control study has shown that offspring of parents who both have CVD have a 90% risk of developing varicose veins, whereas the risks 25% for male and 62% for female offspring when one parent is affected.<xref rid="cit0016" ref-type="bibr">16</xref> The result of analysis nuclear families is compatible with autosomal dominant inheritance for 70%-92%, some pedigrees being compatible with autosomal recessive inheritance, whereas 37% of cases are sporadic.<xref rid="cit0016" ref-type="bibr">16</xref> There is evidence that varicose veins disease are linked to mutation of FOXC2 gene (associated with lymphedema-distichiasis syndrome), Notch 3 gene (associated with cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy), angiodysplasia (Ehlers-Danlos syndrome, Klippel-Trenaunay syndrome) and the Norries disease gene (associated with ocular anomaly and sensory neural deafness).<xref rid="cit0017" ref-type="bibr">17</xref> Furthermore, many inherited metabolic disorders are associated with CVD, particularly hyperhomocysteinemia, and genetic influences on wall remodelling.<xref rid="cit0017" ref-type="bibr">17</xref> There are had limited data concerning a possible correlation between family history and chronic venous ulcer.<xref rid="cit0017" ref-type="bibr">17</xref> In the West London Study, in which patients with leg ulcers were studied over one-year period, the prevalence of such ulcers was higher in white than in a South Asian individuals (odds ratio=4.43).<xref rid="cit0018" ref-type="bibr">18</xref> However, history of DVT, age, arterial hypertension and prolonged standing are the main factors in the development of ulcers.<xref rid="cit0017" ref-type="bibr">17</xref> However, whether there is a correlation between family history and venous ulcer is subject to ongoing debated.<xref rid="cit0017" ref-type="bibr">17</xref> Apart from an established associated between occurrence of venous ulcers and familial abnormality in iron mechanism such as hemochromatosis, estrogen receptor beta gene and hereditary thrombophilia.<xref rid="cit0017" ref-type="bibr">17</xref> In our patients, those in the C6 category were more likely to have a family history of CVD.</p><p>In this study, the superficial venous system was the commonest site of venous reflux in this study (GSV, 67.32%; SSV, 16.99%). Reflux was also common in perforator veins (45.10%) and deep veins (12.42%). SSV and perforator reflux were associated with increased risk of severe CVD. Additionally, the more numerous the venous systems involved, the greater the risk of severe CVD; this association was significant. In this study, only one venous system was involved in 48% of participants; however, almost half of the patients with severe CVD had involvement of two venous systems. A previous study showed a high prevalence (more than 80%) of superficial vein reflux in Thai patients.<xref rid="cit0019" ref-type="bibr">19</xref> Other Asian studies have reported similar findings, including studies from Hong Kong (93%)<xref rid="cit0020" ref-type="bibr">20</xref> and Japan (90%)<xref rid="cit0021" ref-type="bibr">21</xref>. Of note, the prevalence of deep vein reflux in the present study was relatively low (12.42%) in present study compared with previous studies from Thailand (63.3%).<xref rid="cit0019" ref-type="bibr">19</xref> Hong Kong (73.3%)<xref rid="cit0020" ref-type="bibr">20</xref> and Japan (51.7%).<xref rid="cit0021" ref-type="bibr">21</xref></p><p>Compression therapy was the main form of treatment administered to the participants; however, only 40% of patients complied well with it. Sclerotherapy, mostly foam sclerotherapy, was used in 20% of our patients. Foam sclerotherapy was used for truncal veins in both the mild to moderate and severe CVD groups; however, patients with severe CVD underwent more sessions than did those with mild to moderate CVD. Liquid sclerotherapy was only used in the mild to moderate CVD group, most patients undergoing one session. Medications were mainly used in the severe CVD group, the most common being micronized purified flavonoid fraction (17.76%), Aescin (12.02%) and sulodexide (1.16%). More than half of patients who received medical treatment (54%) received combined drug therapy. Only 14% of patients underwent surgery, the main procedure being endovenous radiofrequency ablation. We considered surgical management in symptomatic patients with clinical classifications of C2 or more. Perforator reflux in patients with C5-C6 disease was treated by thermal ablation or ultrasound guided foam sclerotherapy. Planning of operative procedures depended on location of venous reflux, severity of CVD and patients&#x02019; preferences. Adjunct stab avulsion was performed on 40% of patients, most of whom had mild to moderate CVD. After these interventions, significant improvements in VCSS categories occurred only in the severe CVD group.</p><p>The present study had some limitations. First, the prevalence of ICVO may have been underestimated because this diagnosis was based only on ultrasound findings (loss of respiratory variation; PPV100%, NPV 81.3%)<xref rid="cit0022" ref-type="bibr">22</xref> and reverse flow in the superior epigastric vein (PPV 100%, NPV 45.3%).<xref rid="cit0022" ref-type="bibr">22</xref> These variables are not the gold standard for diagnosis and depend on the operator. Second, there may have been selection bias as a result of clinician preferences. Third, this was a cross-sectional study, meaning that data were extracted from medical records and patients were not randomized. Thus, unrecognized confounding factors could have introduced bias, and weakening our conclusions. Last, data on symptom improvement after treatment interventions were not available. Moreover, only one participating hospital had data on non-Thai individuals. Further large studies are needed to clarify the epidemiology of CVD in Thai individuals.</p></sec><sec id="s0005"><title>Conclusions</title><p>The major risk factors for severe CVD identified in this study were history of DVT, BMI&#x0003e;30 and older age. The most common CEAP category was C2 (39%). GSV was the most commonly involved venous system. Involvement of numerous venous systems was a risk factor for severe CVD.</p></sec></body><back><ack><title>Acknowledgments</title><p>The author thank all patients and staff of Chulabhorn Hospital for their assistance and support towards the success and completion of this study. The author also thank Dr Trish Reynolds, MBBS, FRACP, from Edanz for editing a draft of this manuscript.</p></ack><sec sec-type="COI-statement" id="s0006"><title>Disclosure</title><p>The author reports no conflicts of interest in this work.</p></sec><ref-list><title>References</title><ref id="cit0001"><label>1.</label><mixed-citation publication-type="journal"><string-name><surname>Vuylsteke</surname>
<given-names>ME</given-names></string-name>, <string-name><surname>Thomis</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Guillaume</surname>
<given-names>G</given-names></string-name>, <string-name><surname>Modliszewski</surname>
<given-names>ML</given-names></string-name>, <string-name><surname>Weides</surname>
<given-names>N</given-names></string-name>, <string-name><surname>Staelens</surname>
<given-names>I</given-names></string-name>. <article-title>Epidemiological study on chronic venous disease in Belgium and Luxembourg: prevalence, risk factors, and symptomatology</article-title>. <source><italic toggle="yes">Eur J Vasc Endovasc Surg</italic></source>. <year>2015</year>;<volume>49</volume>(<issue>4</issue>):<fpage>432</fpage>&#x02013;<lpage>439</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.ejvs.2014.12.031</pub-id><pub-id pub-id-type="pmid">25701071</pub-id></mixed-citation></ref><ref id="cit0002"><label>2.</label><mixed-citation publication-type="journal"><string-name><surname>Criqui</surname>
<given-names>MH</given-names></string-name>, <string-name><surname>Jamosmos</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Fronek</surname>
<given-names>A</given-names></string-name>, et al. <article-title>Chronic venous disease in an ethnically diverse population: the San Diego Population Study</article-title>. <source><italic toggle="yes">Am J Epidemiol</italic></source>. <year>2003</year>;<volume>158</volume>:<fpage>448</fpage>&#x02013;<lpage>456</lpage>. doi:<pub-id pub-id-type="doi">10.1093/aje/kwg166</pub-id><pub-id pub-id-type="pmid">12936900</pub-id></mixed-citation></ref><ref id="cit0003"><label>3.</label><mixed-citation publication-type="journal"><string-name><surname>Sam</surname>
<given-names>RC</given-names></string-name>, <string-name><surname>Hobbs</surname>
<given-names>SD</given-names></string-name>, <string-name><surname>Darvall</surname>
<given-names>KA</given-names></string-name>, et al. <article-title>Chronic venous disease in a cohort of healthy UK Asian men</article-title>. <source><italic toggle="yes">Eur J Vasc Endovasc Surg</italic></source>. <year>2007</year>;<volume>34</volume>:<fpage>92</fpage>&#x02013;<lpage>96</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.ejvs.2006.12.034</pub-id><pub-id pub-id-type="pmid">17408993</pub-id></mixed-citation></ref><ref id="cit0004"><label>4.</label><mixed-citation publication-type="journal"><string-name><surname>Subramanian</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Patel</surname>
<given-names>V</given-names></string-name>, <string-name><surname>Jacobs</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Myles</surname>
<given-names>F</given-names></string-name>, <string-name><surname>Derodra</surname>
<given-names>J</given-names></string-name>. <article-title>Superficial venous pathology in the Asian population of South West London-a prospective study</article-title>. <source><italic toggle="yes">Eur J Vasc Endovasc Surg</italic></source>. <year>2007</year>;<volume>33</volume>:<fpage>747</fpage>&#x02013;<lpage>750</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.ejvs.2006.12.007</pub-id><pub-id pub-id-type="pmid">17270472</pub-id></mixed-citation></ref><ref id="cit0005"><label>5.</label><mixed-citation publication-type="journal"><string-name><surname>Hobbs</surname>
<given-names>SD</given-names></string-name>, <string-name><surname>Sam</surname>
<given-names>R</given-names></string-name>, <string-name><surname>Rehman</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Marshall</surname>
<given-names>T</given-names></string-name>, <string-name><surname>Wilmink</surname>
<given-names>AB</given-names></string-name>, <string-name><surname>Bradbury</surname>
<given-names>AW</given-names></string-name>. <article-title>The utilisation of superficial venous surgery for chronic venous insufficiency by the UK Asian population</article-title>. <source><italic toggle="yes">Eur J Vasc Endovasc Surg</italic></source>. <year>2003</year>;<volume>26</volume>:<fpage>322</fpage>&#x02013;<lpage>324</lpage>. doi:<pub-id pub-id-type="doi">10.1053/ejvs.2002.2001</pub-id><pub-id pub-id-type="pmid">14509898</pub-id></mixed-citation></ref><ref id="cit0006"><label>6.</label><mixed-citation publication-type="book"><string-name><surname>Jonathan</surname>
<given-names>DB</given-names></string-name>, <string-name><surname>Peter</surname>
<given-names>AG</given-names></string-name>. <source><italic toggle="yes">Vascular and Endovascular Surgery</italic></source>. <edition>3rd</edition> ed. <publisher-loc>Philadelphia, USA</publisher-loc>: <publisher-name>Saunders</publisher-name>; <year>2006</year>.</mixed-citation></ref><ref id="cit0007"><label>7.</label><mixed-citation publication-type="journal"><string-name><surname>Sameer</surname>
<given-names>AM</given-names></string-name>, <string-name><surname>Srinivas</surname>
<given-names>P</given-names></string-name>. <article-title>Varicose veins: a Clinical Study</article-title>. <source><italic toggle="yes">Int Surg J</italic></source>. <year>2016</year>;<volume>4</volume>(<issue>2</issue>):<fpage>529</fpage>&#x02013;<lpage>533</lpage>.</mixed-citation></ref><ref id="cit0008"><label>8.</label><mixed-citation publication-type="book"><string-name><surname>Robert</surname>
<given-names>BR</given-names></string-name>. <source><italic toggle="yes">Vascular Surgery</italic></source>. <edition>6th</edition> ed. Vol. <volume>1</volume>. <publisher-loc>Philadelphia, USA</publisher-loc>: <publisher-name>Saunders</publisher-name>; <year>2005</year>.</mixed-citation></ref><ref id="cit0009"><label>9.</label><mixed-citation publication-type="journal"><string-name><surname>Rabe</surname>
<given-names>E</given-names></string-name>, <string-name><surname>Pannier-Fisher</surname>
<given-names>F</given-names></string-name>, <string-name><surname>Bromen</surname>
<given-names>K</given-names></string-name>. <article-title>Bonner Venenstudie der Deutschen Gesellschaft f&#x000fc;r Phlebologie e epidemiologische Untersuchung zur Frage der H&#x000e4;ufigkeit und Auspr&#x000e4;gung von chronischen Venenkrankheiten in der st&#x000e4;dtischen und l&#x000e4;nd- lichen Wohnbev&#x000f6;lkerung</article-title>. <source><italic toggle="yes">Phlebologie</italic></source>. <year>2003</year>;<volume>32</volume>:<fpage>1</fpage>&#x02013;<lpage>14</lpage>. <comment>in German</comment>. doi:<pub-id pub-id-type="doi">10.1055/s-0037-1617353</pub-id></mixed-citation></ref><ref id="cit0010"><label>10.</label><mixed-citation publication-type="journal"><string-name><surname>Evan</surname>
<given-names>CG</given-names></string-name>, <string-name><surname>Fowkes</surname>
<given-names>FGR</given-names></string-name>, <string-name><surname>Ruckley</surname>
<given-names>CV</given-names></string-name>, <string-name><surname>Lee</surname>
<given-names>AJ</given-names></string-name>. <article-title>Prevalence of varicose veins and chronic venous insufficiency in men and women in the general population: Edinburgh Vein Study</article-title>. <source><italic toggle="yes">J Epidemiol Community Health</italic></source>. <year>1999</year>;<volume>53</volume>:<fpage>149</fpage>&#x02013;<lpage>153</lpage>. doi:<pub-id pub-id-type="doi">10.1136/jech.53.3.149</pub-id><pub-id pub-id-type="pmid">10396491</pub-id></mixed-citation></ref><ref id="cit0011"><label>11.</label><mixed-citation publication-type="journal"><string-name><surname>Rabe</surname>
<given-names>E</given-names></string-name>. <article-title>Vein Bonn Study</article-title>. <source><italic toggle="yes">Phlebologie</italic></source>. <year>2006</year>;<volume>2006</volume>:<fpage>179</fpage>&#x02013;<lpage>186</lpage>. <comment>in German</comment>.</mixed-citation></ref><ref id="cit0012"><label>12.</label><mixed-citation publication-type="journal"><string-name><surname>Rabe</surname>
<given-names>E</given-names></string-name>, <string-name><surname>Regnier</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Goron</surname>
<given-names>F</given-names></string-name>, <string-name><surname>Salmat</surname>
<given-names>G</given-names></string-name>, <string-name><surname>Pannier</surname>
<given-names>F</given-names></string-name>. <article-title>The prevalence, disease characteristics and treatment of chronic venous disease: an international web-based survey</article-title>. <source><italic toggle="yes">J Comp Eff Res</italic></source>. <year>2020</year>;<volume>9</volume>(<issue>17</issue>):<fpage>1205</fpage>&#x02013;<lpage>1218</lpage>. doi:<pub-id pub-id-type="doi">10.2217/cer-2020-0158</pub-id><pub-id pub-id-type="pmid">33079592</pub-id></mixed-citation></ref><ref id="cit0013"><label>13.</label><mixed-citation publication-type="journal"><string-name><surname>Beebe-Dimmer</surname>
<given-names>JL</given-names></string-name>, <string-name><surname>Pfeifer</surname>
<given-names>JR</given-names></string-name>, <string-name><surname>Engle</surname>
<given-names>JS</given-names></string-name>, <string-name><surname>Schottenfeld</surname>
<given-names>D</given-names></string-name>. <article-title>The epidemiology of chronic venous insufficiency and varicose veins</article-title>. <source><italic toggle="yes">Ann Epidemiol</italic></source>. <year>2005</year>;<volume>15</volume>:<fpage>175</fpage>&#x02013;<lpage>184</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.annepidem.2004.05.015</pub-id><pub-id pub-id-type="pmid">15723761</pub-id></mixed-citation></ref><ref id="cit0014"><label>14.</label><mixed-citation publication-type="journal"><string-name><surname>Fiebig</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Krusche</surname>
<given-names>P</given-names></string-name>, <string-name><surname>Wolf</surname>
<given-names>A</given-names></string-name>, et al. <article-title>Heritability of chronic venous disease</article-title>. <source><italic toggle="yes">Hum Genet</italic></source>. <year>2010</year>;<volume>127</volume>:<fpage>669</fpage>&#x02013;<lpage>674</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s00439-010-0812-9</pub-id><pub-id pub-id-type="pmid">20354728</pub-id></mixed-citation></ref><ref id="cit0015"><label>15.</label><mixed-citation publication-type="book"><string-name><surname>Niermann</surname>
<given-names>H</given-names></string-name>. <source><italic toggle="yes">Zwillingsdermatologie</italic></source>. Vol. <volume>1</volume>. <publisher-loc>Berlin</publisher-loc>: <publisher-name>Springer-Verlag</publisher-name>; <year>1964</year>:<fpage>32</fpage>&#x02013;<lpage>33</lpage>.</mixed-citation></ref><ref id="cit0016"><label>16.</label><mixed-citation publication-type="journal"><string-name><surname>Cornu-Thenard</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Boivin</surname>
<given-names>P</given-names></string-name>, <string-name><surname>Baud</surname>
<given-names>JM</given-names></string-name>, <string-name><surname>De Vincenzi</surname>
<given-names>I</given-names></string-name>, <string-name><surname>Carpentier</surname>
<given-names>PH</given-names></string-name>. <article-title>Importance of the familial factor in varicose disease. Clinical study of 134 families</article-title>. <source><italic toggle="yes">J Dermatol Surg Oncol</italic></source>. <year>1994</year>;<volume>20</volume>:<fpage>318</fpage>&#x02013;<lpage>326</lpage>. doi:<pub-id pub-id-type="doi">10.1111/j.1524-4725.1994.tb01631.x</pub-id><pub-id pub-id-type="pmid">8176043</pub-id></mixed-citation></ref><ref id="cit0017"><label>17.</label><mixed-citation publication-type="journal"><string-name><surname>Bolsseau</surname>
<given-names>MR</given-names></string-name>. <article-title>Chronic venous disease and the genetic influence</article-title>. <source><italic toggle="yes">Phlebolymphology</italic></source>. <year>2014</year>;<volume>21</volume>(<issue>2</issue>):<fpage>100</fpage>&#x02013;<lpage>111</lpage>.</mixed-citation></ref><ref id="cit0018"><label>18.</label><mixed-citation publication-type="journal"><string-name><surname>Franks</surname>
<given-names>PJ</given-names></string-name>, <string-name><surname>Morton</surname>
<given-names>N</given-names></string-name>, <string-name><surname>Campbell</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Moffatt</surname>
<given-names>CJ</given-names></string-name>. <article-title>Leg ulceration and ethnicity: a study in west London</article-title>. <source><italic toggle="yes">Public Health</italic></source>. <year>1997</year>;<volume>111</volume>:<fpage>327</fpage>&#x02013;<lpage>329</lpage>.<pub-id pub-id-type="pmid">9308383</pub-id></mixed-citation></ref><ref id="cit0019"><label>19.</label><mixed-citation publication-type="journal"><string-name><surname>Kanchanabat</surname>
<given-names>B</given-names></string-name>, <string-name><surname>Stapanavatr</surname>
<given-names>W</given-names></string-name>. <article-title>Venous ultrasonography findings and clinical correlation in 104 Thai patients with chronic venous insufficiency of the legs</article-title>. <source><italic toggle="yes">Singapore Med J</italic></source>. <year>2018</year>;<volume>59</volume>(<issue>3</issue>):<fpage>155</fpage>&#x02013;<lpage>158</lpage>. doi:<pub-id pub-id-type="doi">10.11622/smedj.2017043</pub-id><pub-id pub-id-type="pmid">28503700</pub-id></mixed-citation></ref><ref id="cit0020"><label>20.</label><mixed-citation publication-type="journal"><string-name><surname>Ting</surname>
<given-names>ACW</given-names></string-name>, <string-name><surname>Cheng</surname>
<given-names>SWK</given-names></string-name>, <string-name><surname>Ho</surname>
<given-names>P</given-names></string-name>, <string-name><surname>Llh</surname>
<given-names>W</given-names></string-name>, <string-name><surname>Cheung</surname>
<given-names>GCY</given-names></string-name>. <article-title>Clinical outcomes and changes in venous hemodynamics after subfascial endoscopic perforating vein surgery</article-title>. <source><italic toggle="yes">Surg Endosc</italic></source>. <year>2003</year>;<volume>17</volume>:<fpage>1314</fpage>&#x02013;<lpage>1318</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s00464-002-8764-3</pub-id><pub-id pub-id-type="pmid">12799891</pub-id></mixed-citation></ref><ref id="cit0021"><label>21.</label><mixed-citation publication-type="journal"><string-name><surname>Yamaki</surname>
<given-names>T</given-names></string-name>, <string-name><surname>Nozaki</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Fujiwara</surname>
<given-names>O</given-names></string-name>, <string-name><surname>Yoshida</surname>
<given-names>E</given-names></string-name>. <article-title>Comparative evaluation of duplex-derived parameters in patients with chronic venous insufficiency: correlation with clinical manifestations</article-title>. <source><italic toggle="yes">J Am Coll Surg</italic></source>. <year>2002</year>;<volume>195</volume>:<fpage>822</fpage>&#x02013;<lpage>830</lpage>. doi:<pub-id pub-id-type="doi">10.1016/S1072-7515(02)01670-8</pub-id><pub-id pub-id-type="pmid">12495315</pub-id></mixed-citation></ref><ref id="cit0022"><label>22.</label><mixed-citation publication-type="journal"><string-name><surname>Sermsathanasawadi</surname>
<given-names>N</given-names></string-name>, <string-name><surname>Pruekprasert</surname>
<given-names>K</given-names></string-name>, <string-name><surname>Pitaksantayothin</surname>
<given-names>W</given-names></string-name>, et al. <article-title>Prevalence, risk factors, and evaluation of iliocaval obstruction in advanced chronic venous insufficiency</article-title>. <source><italic toggle="yes">J Vasc Surg</italic></source>. <year>2019</year>;<volume>7</volume>(<issue>3</issue>):<fpage>1</fpage>&#x02013;<lpage>7</lpage>.<pub-id pub-id-type="pmid">30554741</pub-id></mixed-citation></ref></ref-list></back></article>
